Loading
A phase 1/2 trial of SL-28 in pancreatic ductal adenocarcinoma, non-small-cell lung cancer, oesophageal cancer, gastric & gastro-oesophageal junction cancer, hepatocellular carcinoma and bladder & urothelial cancer, run by Second Life Therapeutics, now recruiting.
SL-28 for Advanced Solid Tumours is a phase 1/2 interventional study registered as NCT07341737 by Second Life Therapeutics, with 60 participants planned, started 2026-08-14 and due to reach its primary completion in 2027-01-01. Interventions recorded: SL-28.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Bladder & urothelial cancer, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/